Richmond 2013.

Methods	NORTRIPTYLINE Randomized controlled trial Setting: 18 prisons, Australia Recruitment: referral from clinic staff, flyers and posters in prisons
Participants	425 male prisoners aged >18, incarcerated for ≥ 1m with ≥ 6m of current sentence remaining, FTND ≥ 5. av age 34, av cpd 23, 83% FTND ≥ 6
Interventions	1. Nortriptyline in tablet form for 13 weeks (TQD week 3. Week 1: 25 mg/day for 3 days, 50 mg/day for 4 days. Weeks 2 to 12 75 mg/day. Week 13 50 mg/day for 4 days, then 25 mg/day for 3 days) 2. Placebo on same schedule Both groups: Two 30 minute counselling sessions with CBT. Self‐help materials, access to quitline. 10 weeks NRT patch started on TQD; 21 mg weeks 1‐6, 14 mg/day weeks 7‐8, 7 mg/day weeks 9‐10.
Outcomes	Continuous abstinence at 12m Validation: CO < 10 ppm
Notes	New for 2013 update N quit extrapolated from percentages provided Funding: National Health and Medical Research Council, NSW Department of Health, Queensland Department of Health. NRT provided free of charge by GlaxoSmithKline.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	“Randomization algorithm,” no further information provided
Allocation concealment (selection bias)	Unclear risk	Not specified
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Identical placebo. “Follow‐up assessments were conducted… by a prison nurse research assistant who was blind to group allocation.” No further information on blinding provided.
Incomplete outcome data (attrition bias) All outcomes	Low risk	80% followed up at 12m, similar in both groups